ck-2 inhibitor 2

CK2 Inhibitor 2, characterized as a potent, selective, and orally active inhibitor of CK2, demonstrates an impressive IC50 value of 0.66 nM. It exhibits high selectivity towards Clk2 with an IC50 of 32.69 nM in comparison to CK2. Furthermore, CK2 Inhibitor 2 has been shown to possess promising antiproliferative and antitumor activities [1].

UCK2 Inhibitor-2 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2) with IC50=3.8 µM that inhibits UCK2-mediated nucleoside recycling in cells.

CK-666 is a cell-permeable inhibitor of the actin-related protein Arp2/3 complex, binding to and stabilizing its inactive state, thereby preventing the movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) configuration.

CK-636 (CK-0944636), an Arp2/3 complex inhibitor, can inhibit actin polymerization induced by the human (IC50: 4 μM), fission yeast (IC50: 24 μM) and bovine (IC50: 32 μM) Arp2/3 complex, respectively.

YTHDF2-IN-1 (Compound CK-75) is an inhibitor of YT521-B homology domain family 2 (YTHDF2) with a dissociation constant (Kd) of 26.2 μM, and it effectively blocks the interaction between YTHDF2 and m6A RNA. It suppresses colony formation in JAR cells and exhibits antiproliferative activity in various cancer cell lines, with an IC50 in the micromolar range. Additionally, YTHDF2-IN-1 induces apoptosis in K562 cells and causes cell cycle arrest at the G0/G1 phase.

CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM) with an IC50 of 86 nM. The compound exhibits IC50 values of 2.3, 42, and 0.58 μM for cardiac myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A), respectively. CK-571 is utilized in research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related disorders.

CK-2-68 is a potent inhibitor of PfNDH2.

CK-869, an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor with an IC50 of 7 μM, is a valuable tool for investigating the Arp2/3 complex.

TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.